Despite its impact on quality of life and potential for complications, specific risk and protective factors for herpes zoster (HZ) after kidney transplantation (KT) remain to be clarified. We included 444 patients undergoing KT between November 2008 and March 2013. Peripheral blood lymphocyte subpopulations were measured at baseline and months 1 and 6. The risk factors for early (first post-transplant year) and late HZ (years 1-5) were separately assessed. We observed 35 episodes of post-transplant HZ after a median follow-up of 48.3 months (incidence rate: 0.057 per 1000 transplant-days). Median interval from transplantation was 18.3 months. Six patients (17.1%) developed disseminated infection. Postherpetic neuralgia occurred in 10 cases (28.6%). The receipt of anticytomegalovirus (CMV) prophylaxis with (val)ganciclovir decreased the risk of early HZ [adjusted hazard ratio (aHR): 0.08; 95% CI: 0.01-1.13; P-value = 0.062], whereas the natural killer (NK) cell at month 6 was protective for the occurrence of late HZ [aHR (per 10-cells/ll increase): 0.94; 95% CI: 0.88-1.00; P-value = 0.054]. In conclusion, two easily ascertainable factors (whether the patient is receiving anti-CMV prophylaxis and the NK cell count at month 6) might be potentially useful to tailor preventive strategies according to individual susceptibility to post-transplant HZ.
Introduction
The reactivation of varicella-zoster virus (VZV) latent infection from cranial nerve or dorsal root ganglia in form of herpes zoster (HZ) represents a notable source of decrease in health-related quality of life in the general population, particularly when followed by postherpetic neuralgia (PHN) [1] . Patients undergoing solid organ transplantation (SOT) face an increased risk of HZ due to the deleterious effect of post-transplant immunosuppression and are more prone to develop potentially lifethreatening forms of disease [2] [3] [4] .
Preventive strategies for post-transplant HZ have been limited, as the use of the live attenuated virus vaccine derived from the Oka VZV strain is contraindicated in immunocompromised hosts [5] . The advent of a new subunit vaccine containing the VZV glycoprotein E and the AS01 B adjuvant system (HZ/su) has opened promising perspectives in the prevention of this condition [6] . No safety or efficacy data are available so far for the SOT population, although clinical trials in kidney transplant (KT) recipients are ongoing (ClinicalTrials.gov identifier: NCT02058589).
Previous studies focused on HZ among KT recipients were performed more than 15 years ago (limiting its applicability to contemporary immunosuppression practices) [2] , jointly considered different SOT populations [3, 7] or suffer from short post-transplant follow-up [4, 8] or lack of data granularity [3] . Most importantly, none of them investigated any surrogate of the VZVspecific host's immune response. By gaining more insight into the factors modulating the susceptibility to this complication, targeted preventive approaches might be focused on those recipients most expected to benefit from certain measures. Thus, we aimed at investigating the incidence and risk factors for HZ in a large singlecenter cohort of KT recipients with long-term follow-up by taking advantage from the immune monitoring program to which these patients were subjected.
Materials and methods

Study population and design
Consecutive adult patients (≥18 years) undergoing KT at our center between November 2008 and March 2013 were included in an immunological monitoring program, as detailed elsewhere [9, 10] . Patients with primary immunodeficiency syndrome, human immunodeficiency virus (HIV) infection, simultaneous pancreaskidney transplantation, or primary graft nonfunction were excluded, as were those who died or developed graft loss requiring graft removal within the first week. Participants were enrolled at the time of transplantation and followed up until March 2016 (unless death or graft loss occurred earlier). They underwent an immune status assessment at scheduled times (baseline [within 12 h before transplantation] and post-transplant months 1 and 6 [AE2 weeks]) that included the enumeration of peripheral blood lymphocyte subpopulations (PBLSs), as detailed below and elsewhere [10] . The research was performed in accordance with the ethical standards defined by the Helsinki Declaration and the Declaration of Istanbul on Organ Trafficking and Transplant Tourism. The local Ethics Committee approved the study protocol, and written informed consent was obtained from all participants.
Pretransplant, perioperative, and post-transplant variables were prospectively recorded by means of a standardized case report form. Additional information on post-transplant HZ episodes was specifically gathered by retrospective chart review. To ensure adequate capture of those mild cases of HZ that could have been treated in an outpatient setting, electronic medical records of primary care physicians were also screened through the Madrid Electronic Health Record (HORUS) system, which integrates comprehensive patient information from the entire regional healthcare system. The primary study outcome was the occurrence of post-transplant HZ. We also assessed the occurrence of complicated post-transplant HZ and PHN as secondary outcomes.
Definitions
Post-transplant HZ was clinically diagnosed on the basis of the appearance of a characteristic pruritic papulovesicular rash with a dermatomal distribution, preceded or not by prodromal pain. Virological (i.e., PCR or cell culture) or immunohistochemical confirmation was not required. Disseminated HZ was defined by the presence of typical lesions involving ≥2 noncontiguous dermatomes or varicella-like syndrome (disseminated vesicular rash with lesions in various stages of evolution). PHN was defined as pain arising or persisting in the areas originally affected by HZ for at least 3 months after the onset of the rash. Complicated HZ was defined by any of the following events: HZ ophthalmicus (conjunctivitis, keratitis, uveitis, or ocular cranial nerve palsy), central nervous system involvement (meningitis, encephalitis, myelitis, or stroke attributable to necrotizing arteritis), or any other visceral involvement with virological or immunohistochemical documentation.
Immunosuppression and prophylaxis regimens
Immunosuppression and prophylaxis regimens used have been previously described [9, 10] and are detailed as Appendix S1. Regarding anti-cytomegalovirus (CMV) prevention strategies, antiviral prophylaxis with intravenous ganciclovir (GCV) (5 mg/Kg daily) followed by oral valganciclovir (val-GCV) (900 mg daily, with dose adjusted for renal function) was scheduled for 6 months in the presence of donor/recipient serological mismatch (D+/RÀ). Seropositive patients (R+) receiving induction therapy with polyclonal antithymocyte globulin (ATG) were scheduled to receive CMV antiviral prophylaxis for 3 months [11, 12] . The initiation of pre-emptive therapy in intermediate-risk patients (R+ not receiving ATG) with documented CMV infection was suggested to the attending physicians, although not systematically performed. Acyclovir prophylaxis was not administered for patients not at risk for CMV infection (DÀ/RÀ). No patient received the live attenuated VZV vaccine either prior to or after transplantation. [14] .
Enumeration of PBLSs
Statistical analysis
Quantitative data were shown as the mean AE standard deviation (SD) or the median with interquartile ranges (IQR), whereas qualitative variables were expressed as absolute and relative frequencies. Categorical variables were compared using the chi-squared test. Student's t-test, Mann-Whitney U-test or Wilcoxon signed-rank test were applied for continuous variables, as appropriate. The optimal cutoff value (i.e., that with the highest value for the combined sensitivity and specificity) of selected PBLSs to predict post-transplant HZ was identified by the Youden's index or J statistic (J = sensitivity + specificity À 1) [15] in the receiver operating characteristics (ROC) curve estimated for time-to-event outcomes. In addition, resampling (bootstrapping) and cross-validation methods were used to assess the variability of the proposed cutoff and to correct for the over-optimism of the risk estimates, in an attempt to minimize the inherent bias induced by model building and estimation of effects within the same data set [16] . We applied the "minimum P-value method" (in which the cutoff is selected such that the P-value for the comparison of observations below and above such a threshold is a minimum) to confirm the validity of the chosen value. The minimum P-value was corrected for overestimation by means of the so-called shrinkage factor. Cross-validation was then carried out among 800 bootstrap samples of equal size generated by sampling with replacement. In each of these bootstrap samples, the optimal cutoff value was also obtained.
The incidence of post-transplant HZ was plotted by Kaplan-Meier curves and differences between groups compared with the log-rank test. Time-to-first-event Cox regression models were used to identify independent risk factors for the occurrence of post-transplant HZ (primary study outcome), with death and graft loss considered as competing risk events. To adequately assess the effect of anti-CMV prophylaxis (that is only administered for 3-6 months), and considering that the overall amount of immunosuppression usually decreases over time, we constructed two separate models to predict the occurrence of HZ during the first 12 months, and thereafter until year 5 after transplantation (early and late HZ, respectively). Only the first episode of HZ recorded for an individual patient within each of these periods was included in the analysis. Certain variables were modeled as time-dependant covariates and forced into the models regardless of its univariate significance. Associations were expressed as HRs with 95% confidence intervals (CIs). All the significance tests were two-tailed. Statistical analysis was performed using SPSS v. 20.0 (IBM Corp., Armonk, NY, USA) and R software (R Foundation for Statistical Computing, Vienna, Austria), whereas graphics were generated with PRISM v. 6.0 (GraphPad Software Inc., La Jolla, CA, USA).
Results
Baseline characteristics and incidence of posttransplant HZ
We included 444 patients whose demographics and baseline characteristics are shown in Table 1 . The median follow-up was 48.3 months (IQR: 22.5-66.4). One-and five-year survival rates were 91.0% and 84.0%, respectively, and 56 patients (12.6%) died at a median interval of 427.0 days after transplantation. Death-censored graft survival at one and five years was 96.0% and 85.0%.
Thirty-five patients were diagnosed with 35 episodes of post-transplant HZ, accounting for a cumulative incidence at the end of follow-up of 7.9% (95% CI: 5.4-10.4%) and an incidence rate of 0.057 per 1,000 transplant-days (95% CI: 0.041-0.079). The median interval between transplantation and diagnosis was 18.3 months (95% CI: 6.1-34.2). Most cases (68.6% [24/35] ) occurred beyond the first post-transplant year, although the incidence rates for both periods were roughly similar (0.066 and 0.048 cases per 1000 transplant-days, for early and late HZ, respectively; Pvalue = 0.417).
Clinical features of post-transplant HZ
The clinical characteristics of the episodes of posttransplant HZ are detailed in Table 2 . Most of them involved a single dermatome and had a thoracic distribution, although almost one-fifth of patients developed a disseminated (i.e., multimetameric or varicella-like) infection. The clinical characteristics of these six episodes of disseminated HZ are detailed in Table S1 . Patients with disseminated HZ were more likely to have been previously given steroid boluses as antirejection therapy, although the difference did not attain statistical significance (50.0% [3/6] vs. 20.7% [6/23] ; P-value = 0.162). They also exhibited a lower CD8 + T-cell count in the preceding monitoring point as compared with those with uncomplicated HZ (0.165 vs. 0.426 9 10 3 cells/ll, respectively; Pvalue = 0.022). The majority of episodes of posttransplant HZ were managed in an outpatient setting, and oral famciclovir was the most commonly administered antiviral drug.
The clinical course was complicated with PHN in approximately one-third of cases. Patients with PHN trended to be older (64.9 AE 13.2 vs. 57.5 AE 15.3 years; P-value = 0.189) and more likely to have received induction therapy with ATG (60.0% [6/10] vs. 32.0% [8/17] ; P-value = 0.151) compared to those remaining free of this complication. There were no differences with regard to the type of antiviral agent used. One single patient-a 71-year-old male who received his first KT 42 months before-had a complicated infection in form of HZ ophthalmicus with keratitis and loss of vision. Of note, he had been previously diagnosed with CMV syndrome and visceral leishmaniasis. There were no recurrences of HZ during the follow-up.
Risk factors for early post-transplant HZ
The results of the uni-and multivariate models of predicting factors for the occurrence of HZ during the first 12 months (early HZ) are depicted in Table 3 . Patients suffering from HZ within this period were older and less likely to have received induction therapy with ATG and CMV antiviral prophylaxis compared to the remaining recipients, whereas no differences were found in PBLS counts at baseline (data not shown) or month 1. There were no significant differences between both groups in the 12-month cumulative incidence of acute graft rejection, and no significant impact was observed either when this variable was included as a timedependant covariate in the model with death and graft loss treated as competing risk events. On the other hand, the receipt of CMV antiviral prophylaxis exerted a near significant protective effect (adjusted HR [aHR]: 0.08; 95% CI: 0.01-1.13; P-value = 0.062). In accordance with this finding, early HZ-free survival was significantly lower among those patients that were not given prophylaxis (12-month survival rate: 94.0% vs. 100.0%; log-rank test P-value = 0.005) (Fig. 1) .
Risk factors for late post-transplant HZ
We next assessed the risk factors for the development of HZ between years 1 and 5 after transplantation (late HZ). As shown in Table 4 , neither the receipt of CMV antiviral prophylaxis nor the occurrence of acute rejection had a significant impact on the incidence of HZ during this period. This lack of association persisted when rejection was analyzed as a time-dependant covariate (data not shown). When comparing PBLSs at months 6, patients with late post-transplant HZ had a significantly lower count of NK cells than those without. The area under the ROC curve for predicting this complication was 0.669 (95% CI: 0.537-0.802) (Fig. S1) . Such an estimate was roughly similar when the ROC curve was plotted for time-to-event outcomes (0.665; 95% CI: 0.521-0.809). The kinetics of NK cell counts demonstrates a notable decrease at month 1 from baseline that only partially recovered at month 6 (Fig. S2) . Recipients suffering from late HZ were also more likely to have been diagnosed with CMV disease within the first 6 months after transplantation. Only the NK cell count remained (aHR [per 10-cells/ll increase]: 0.94; 95% CI: 0.88-1.00; P-value = 0.054) in the final multivariate model in which the use of CMV antiviral prophylaxis was forced despite its lack of univariate significance.
To further refine the analysis of the predictive accuracy of this parameter, we explored different thresholds (including the median and first and third quartiles) and selected a cutoff value of 0.040 9 10 3 NK cells/ll as that with the highest Youden's index (sensitivity: 42.9%; 95% CI: 17.7-71.1; specificity: 76.0%; 95% CI: 70.7-80.9) (Table S2 ). Such cutoff offered the best positive predictive value (11.4%; 95% CI: 5.7-21.5) without significantly compromising negative predictive value (96.5%; 95% CI: 94.9-97.6). In addition, this threshold was also selected as the optimal according to the "minimum P-value method" (unadjusted HR: 3.26; 95% CI: 1.11-9.55; P-value = 0.031), even after correction for over-optimism (shrinkage factor: 0.78). Cross-validation confirmed that the NK cell count of 0.040 9 10 3 cells/ll was the optimal cutoff value in 270 of 800 bootstrap samples (33.7%), being the highest rate among the various alternative points explored (Table S2) . Overall, 14.3% (58/404) of patients with evaluable NK cell measurement at month 6 were below this cutoff. As expected, late HZ-free survival was significantly lower among patients with NK cell counts below this threshold at month 6 compared to those above (5-year survival rate: 88.0% vs. 96.0%, respectively; log-rank test P-value = 0.015) (Fig. 1) . The deleterious impact of having a NK cell count <0.040 9 10 3 cells/ll at month 6 was not confirmed in the multivariate Cox regression model with death and graft loss as competing risk events (aHR: 2.51; 95% CI: 0.77-8.19; P-value = 0.126).
We additionally analyzed the predictive value of the NK cell count at month 6 by stratifying the incidence of late HZ according to ascending categories of this variable (<0.040, 0.040-0.120, 0.120-0.250, and >0.250 9 10 3 cells/ll). There was a clear gradient in the cumulative incidence at year 5 across these categories (11.4% [5/ [4/106] , and 0.0% [0/46], respectively; P-value = 0.074), although the low number of events in each interval precludes the demonstration of significant differences in survival curves (logrank test P-value = 0.053). However, when the central categories were collapsed into a single one, differences in late HZ-free survival were also evident (5-year survival rates: 88.0%, 95%, and 100.0% for <0.040, 0.040-0.250, and >0.250 9 10 3 cells/ll, respectively; log-rank test P-value = 0.023) (Fig. S3) .
Discussion
Post-transplant HZ constitutes a non-negligible complication for KT recipients, as demonstrated by the cumulative incidence in the present cohort (7.9%). Other authors have reported similar figures [2, 4] , although follow-up periods were not homogeneous across studies. PBLSs: peripheral blood lymphocyte subpopulations; R: recipient; SD: standard deviation. *Data available for 440 patients. †HRs per 10-cells/ll increase in NK cell count at month 6. ‡Percentages were calculated after excluding patients with pretransplant diabetes mellitus. ¶Infection requiring hospital admission and parenteral antibiotic therapy.
Despite advances in immunosuppression and posttransplant care, the burden due to post-transplant HZ has remained largely unchanged over the last decades, as suggested by comparison of our incidence rate between 2008 and 2013 (0.057 episodes per 1000 transplant-days) to that observed in the US Veterans Administration between 1996 and 2007 (0.068 per 1000 transplant-days) [3] . Moreover, the rates of PHN found by us and others [2, 4, 8] more than triple that of the overall population [17] . The median interval to the occurrence of HZ in the present study (18.3 months) was similar to [4] or larger than those previously reported [8, 18] . Although more than a third of the cases accumulated within the 12 months, the period at risk spanned thereafter through the following years. Such a case distribution suggests that the assessment of risk factors for posttransplant HZ should take into account the relative role of different conditions across time. By separately analyzing two different post-transplant timeframes (first year [early HZ] and from years 1 to 5 [late HZ]), we have identified some factors that appear to influence individual susceptibility for each period: the receipt of (val-) GCV and a low NK cell count at month 6, respectively. This study design seems reasonable as the effect of certain variables, such as the receipt of anti-CMV prophylaxis, may be evident only for limited post-transplant periods and would have otherwise remained hidden in a single comprehensive analysis spanning the 5-year period.
The in vitro activity of CGV against VZV has been shown to be similar to that of acyclovir [19, 20] . It has been accordingly proposed that SOT recipients already receiving (val-)GCV to prevent CMV infection may be safely spared specific prophylaxis with acyclovir or it prodrugs against herpes simplex virus (HSV) or VZV [21] . However, clinical data supporting this recommendation is relatively scarce, in particular regarding HZ, and the results from various studies have been not entirely conclusive [3, 4, 7, 8, 22] . A recent subanalysis from the Swiss Transplant Cohort Study (STCS) found that SOT recipients on anti-CMV prophylaxis had a lower incidence of overall infection due to a-herpesviruses (mainly HSV), although this protective effect could not be specifically proven for HZ despite the large number of patients included [7] . Other authors have been unable to ascertain the impact of anti-CMV agents on the incidence of post-transplant HZ, either due to the universal use of (val-)GCV prophylaxis in the analyzed cohort [4] or to the lack of specific data [3] . In addition, some studies directly compared the effect of prophylaxis with anti-CMV and anti-HSV agents, reporting a nonsignificant trend toward a lower incidence of HZ among KT recipients under (val-)GCV as compared to those receiving acyclovir or its derivatives [2] . However, the administration of specific anti-HSV prophylaxis among CMV DÀ/RÀ patients in daily clinical practice is far from universal [7] . Of note, none of our patients that were not subjected to anti-CMV prophylaxis received acyclovir or any of its derivatives to prevent a-herpesvirus infection, regardless of their CMV D/R serostatus. This circumstance may have contributed to delineate more clearly the protective effect of (val-)GCV primarily given to prevent CMV infection. In fact, none of our patients developed HZ while on CMV antiviral prophylaxis, similarly to previous reports from heart transplant recipients [23] . Nevertheless, it should be stressed that we could only demonstrate a borderline significant protective effect of CMV antiviral prophylaxis on the risk of early HZ, likely reflecting insufficient statistical power due to the low number of events.
Acute graft rejection has been found to increase the risk of HZ in some [4] but not all [2, 7] previous studies. Interestingly, after incorporating death and graft loss as competing risk events in the regression model, we found no apparent impact of such a complication on the occurrence of either early or late HZ. Likewise, the receipt of anti-CMV prophylaxis seems to outweigh the predictive value of recipient's age, which had been identified by other authors [2] [3] [4] .
Albeit still preliminary, a noteworthy finding of the present study is that low NK cell counts at month 6 appear to increase the risk for HZ over the following years. As for other herpesviruses, the competency of cellmediated immunity is instrumental to prevent VZV from reactivating. There is mounting evidence on the protective role of VZV-specific T cells among different immunocompromised populations [24] [25] [26] . It has been also reported that percentage of VZV-specific CD8 + effector memory T cells is significantly lower in KT recipients than in controls [27] . However, current methods for the enumeration of VZV-specific T cells-based on in vitro release of interferon-c or other Th 1 cytokines upon antigen stimulation-are technically demanding and not standardized, and their implementation in clinical practice seems unfeasible in the medium term [26, 28] . Although limited by the lack of an independent validation cohort, our study suggests that the NK cell count may be used as a convenient surrogate for the VZV-specific cellmediated immunity. One of the hallmarks of NK cells is their ability to display potent cytolytic activity without the need of previous clonal expansion and differentiation. Our group has recently shown that liver transplant recipients with low NK cell counts have an increased risk of opportunistic infection [29] . The relevance of NK cells in the host-pathogen interaction that leads to VZV dissemination or reactivation following primary infection is exemplified by the occurrence of severe forms of varicella among patients with NK cell deficiencies [30, 31] . The increased risk of HZ associated with therapy with bortezomib in hematologic patients has been linked to the impact of this agent on NK and CD8 + T-cell counts [32] . On the other hand, we cannot rule out that NK cell counts might to some extent mirror the enumeration of VZV-specific CD4 + or CD8 + T cells. The lack of significant differences in NK cell counts at baseline or month 1 between patients with or without HZ supports the notion that anti-CMV prophylaxis acts a protective factor for this complication and that such effect appears strong enough to mute the impact of host's immune response. By assuming this hypothesis, it seems reasonable that the predictive value of the NK cell count could only emerge once prophylaxis has been discontinued. On the other hand, the dispersion observed in NK cell counts at month 6 was higher than at month 1 (Fig. S2) , suggesting that the former measurement point would become more informative as the overall amount of immunosuppression gradually decreases (i.e., patients with persistently low NK cell counts remain more susceptible to HZ as compared to those that recover their baseline levels).
The present study has some limitations. Despite the large sample size, the relatively low number of episodes of HZ may have compromised the stability of multivariate models. Accordingly, associations only approached borderline statistical significance after multivariate adjustment. This caution is particularly necessary for interpreting the proposed cutoff value of the NK cell count at month 6, which should be taken as merely tentative. Although the study cohort was prospectively assembled, details on post-transplant HZ were retrospectively collected and we cannot rule out that some cases could have been missed. A more frequent monitoring of PBLSs would have been desirable to accurately delineate their post-transplant kinetics and potential impact on the development of HZ. Unfortunately, our immune monitoring schedule only spanned the first 6-month period after transplantation, thus lacking serial measurements of NK cell counts beyond that point and closer to the time of occurrence of HZ.
To conclude, HZ is still a relevant event during the course following KT both in terms of incidence and negative impact on quality of life. Two easily ascertainable factors (whether the patient is receiving or not anti-CMV antiviral prophylaxis and the NK cell count at post-transplant month 6) might be potentially useful to tailor preventive strategies according to individual susceptibility [21] . These would eventually include the use of anti-VZV prophylaxis with acyclovir or derivatives beyond the sixth month after transplantation, the tapering of immunosuppression, and the preferential administration-upon approval for this patient population-of the novel HZ/su vaccine for recipients with low NK cell counts. 
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